Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

S2k Leitlinie: Diagnostik und Therapie des chronischen Pruritus (2022) Ständer S, Zeidler C, Augustin M, Darsow U, Kremer A, Legat FJ, Koschmieder S, et al. Journal article S2k guideline: Diagnosis and treatment of chronic pruritus (2022) Ständer S, Zeidler C, Augustin M, Darsow U, Kremer A, Legat FJ, Koschmieder S, et al. Journal article The Gut–Immune–Brain Axis: An Important Route for Neuropsychiatric Morbidity in Inflammatory Bowel Disease (2022) Masanetz RK, Winkler J, Winner B, Günther C, Süß P Journal article, Review article Very Low-Volume, High-Intensity Interval Training Mitigates Negative Health Impacts of COVID-19 Pandemic-Induced Physical Inactivity (2022) Reljic D, Eichhorn A, Herrmann HJ, Neurath M, Zopf Y Journal article, Original article Long-term results of teduglutide treatment for chronic intestinal failure – Insights from a national, multi-centric patient home-care service program (2022) Greif S, Maasberg S, Wehkamp J, Fusco S, Zopf Y, Herrmann HJ, Lamprecht G, et al. Journal article, Original article Nahrungsmittelunverträglichkeiten: Mit vorwiegend gastrointestinaler Symptomatik (2022) Zopf Y, Dieterich W Journal article Real-time colorectal polyp detection using a novel computer-aided detection system (CADe): a feasibility study (2022) Soons E, Rath T, Hazewinkel Y, Van Dop WA, Esposito D, Testoni PA, Siersema PD Journal article HLA-DO: a possible switch between GvHD and GvL effect (2022) Zeun J, Neubeck S, Lang V, Flamann C, Nagel L, Kunert T, Vogler T, et al. Conference contribution Arginase 1 functions as anti-resolvin in inflammatory bowel disease (2022) Nuese B, Gänsbauer M, Baier J, Mattner J, Gerlach R, Wirtz S, Rauh M Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution